Investigation of the effect of canagliflozin on the disposition index, a marker of pancreatic beta cell function, in patients with type 2 diabetes

Takahara, Mitsuyoshi; Shiraiwa, Toshihiko; Matsuoka, Taka-aki; Yamamoto, Kaoru; Maeno, Yoshifumi; Shiraiwa, Yuka; Yoshida, Yoko; Katakami, Naoto; Iijima, Hiroaki; Katsumata, Hideyuki; Arakawa, Kenji; Hashimoto, Toshio; Shimomura, Iichiro

doi:https://doi.org/10.2147/DMSO.S273396

Investigation of the effect of canagliflozin on the disposition index, a marker of pancreatic beta cell function, in patients with type 2 diabetes

Takahara, Mitsuyoshi; Shiraiwa, Toshihiko; Matsuoka, Taka-aki et al.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, 13, 4457-4468

アクセス数:1,785件（2025-08-15 23:02 集計）

固定URL: https://hdl.handle.net/11094/78261

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
dmso_13_4457	pdf	なし	835 KB	347	2021.01.14

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Investigation of the effect of canagliflozin on the disposition index, a marker of pancreatic beta cell function, in patients with type 2 diabetes
著者	NRID 1000000751067 1000000751067 researchmap permalink takahara-mitsuyoshi takahara-mitsuyoshi Scopus Author ID 35933605700 35933605700 著者名 Takahara, Mitsuyoshi
	著者名 Shiraiwa, Toshihiko
	NRID 1000010379258 1000010379258 著者名 Matsuoka, Taka-aki
	著者名 Yamamoto, Kaoru
	著者名 Maeno, Yoshifumi
	著者名 Shiraiwa, Yuka
	著者名 Yoshida, Yoko
	NRID 1000010403049 1000010403049 researchmap permalink naoto.katakami naoto.katakami Scopus Author ID 7003392840 7003392840 著者名 Katakami, Naoto
	著者名 Iijima, Hiroaki
	著者名 Katsumata, Hideyuki
	著者名 Arakawa, Kenji
	著者名 Hashimoto, Toshio
	NRID 1000060346145 1000060346145 researchmap permalink shimomura_i shimomura_i Scopus Author ID 7006715546 7006715546 ORCID 0000-0002-0851-9603 0000-0002-0851-9603 著者名 Shimomura, Iichiro
キーワード等	Beta cell function
	Canagliflozin
	Glimepiride
	Glycemic control
	Type 2 diabetes mellitus
内容	This article is published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 18 November 2020, Volume 2020:13, Pages 4457-4468.
抄録	Aim: Our aim was to investigate the effects of add-on canagliflozin with glimepiride dose adjustment or glimepiride dose adjustment on pancreatic beta cell function in patients with type 2 diabetes mellitus and inadequate glycemic control despite stable triple therapy (metformin, teneligliptin, and glimepiride) plus diet/exercise therapy. Methods: Forty patients on stable triple therapy were randomized to glimepiride dose adjustment without (glimepiride group) or with add-on canagliflozin 100 mg (canagliflozin group) for 24 weeks. The glimepiride dose was adjusted every 4 weeks based on continuous glucose monitoring over the previous 2 weeks according to a prespecified algorithm. After the 24-week treatment period, the patients returned to the pre-intervention regimen for 1 week (wash-out period). Patients underwent 75 g OGTTs at the start of the run-in period and at the end of the wash-out period. The primary endpoint was the change in disposition index (DI). Results: Thirty-nine patients completed the study (canagliflozin, n = 19; glimepiride, n = 20). The change in DI was +5.1% and −11.0% in the canagliflozin and glimepiride groups, respectively, with a between-group difference ratio of 18.0% (P = 0.330). HbA1c, fasting plasma glucose, body weight, and daily-life continuous glucose monitoring-derived para-meters improved in the canagliflozin group. Hypoglycemia occurred in 60% (44 episodes) and 70% (79 episodes) of patients in the canagliflozin and glimepiride groups, respectively. The change in DI was significantly correlated with the changes in glycemic control and variability in overall cohort. Conclusion: Adding canagliflozin to the triple therapy improved beta cell function by 18%, but it did not reach statistical significance. This study also demonstrated a correlation between the change in DI and glycemic control. As canagliflozin improved both glucose level and variability with relatively lower risk of hypoglycemia compared with glimepiride dose adjustment, adding canagliflozin to the triple therapy may be clinically beneficial.
出版者	Dove Medical Press Ltd
収録物名	Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
巻(号)	13
ページ	4457-4468
刊行年月	2020-11-18
言語	英語
ハンドルURL	https://hdl.handle.net/11094/78261
eISSN	11787007
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.2147/DMSO.S273396
アクセス権	open access
権利情報
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020, 13, p. 4457-4468
DC.title	Investigation of the effect of canagliflozin on the disposition index, a marker of pancreatic beta cell function, in patients with type 2 diabetes
DC.creator	Takahara, Mitsuyoshi
	Shiraiwa, Toshihiko
	Matsuoka, Taka-aki
	Yamamoto, Kaoru
	Maeno, Yoshifumi
	Shiraiwa, Yuka
	Yoshida, Yoko
	Katakami, Naoto
	Iijima, Hiroaki
	Katsumata, Hideyuki
	Arakawa, Kenji
	Hashimoto, Toshio
	Shimomura, Iichiro
DC.publisher	Dove Medical Press Ltd
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2020-11-18
DC.identifier	https://doi.org/10.2147/DMSO.S273396
DC.subject	Beta cell function
	Canagliflozin
	Glimepiride
	Glycemic control
	Type 2 diabetes mellitus
DC.description	This article is published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 18 November 2020, Volume 2020:13, Pages 4457-4468.
DCTERMS.abstract	Aim: Our aim was to investigate the effects of add-on canagliflozin with glimepiride dose adjustment or glimepiride dose adjustment on pancreatic beta cell function in patients with type 2 diabetes mellitus and inadequate glycemic control despite stable triple therapy (metformin, teneligliptin, and glimepiride) plus diet/exercise therapy. Methods: Forty patients on stable triple therapy were randomized to glimepiride dose adjustment without (glimepiride group) or with add-on canagliflozin 100 mg (canagliflozin group) for 24 weeks. The glimepiride dose was adjusted every 4 weeks based on continuous glucose monitoring over the previous 2 weeks according to a prespecified algorithm. After the 24-week treatment period, the patients returned to the pre-intervention regimen for 1 week (wash-out period). Patients underwent 75 g OGTTs at the start of the run-in period and at the end of the wash-out period. The primary endpoint was the change in disposition index (DI). Results: Thirty-nine patients completed the study (canagliflozin, n = 19; glimepiride, n = 20). The change in DI was +5.1% and −11.0% in the canagliflozin and glimepiride groups, respectively, with a between-group difference ratio of 18.0% (P = 0.330). HbA1c, fasting plasma glucose, body weight, and daily-life continuous glucose monitoring-derived para-meters improved in the canagliflozin group. Hypoglycemia occurred in 60% (44 episodes) and 70% (79 episodes) of patients in the canagliflozin and glimepiride groups, respectively. The change in DI was significantly correlated with the changes in glycemic control and variability in overall cohort. Conclusion: Adding canagliflozin to the triple therapy improved beta cell function by 18%, but it did not reach statistical significance. This study also demonstrated a correlation between the change in DI and glycemic control. As canagliflozin improved both glucose level and variability with relatively lower risk of hypoglycemia compared with glimepiride dose adjustment, adding canagliflozin to the triple therapy may be clinically beneficial.
DC.rights
DC.format	78261
citation_title	Investigation of the effect of canagliflozin on the disposition index, a marker of pancreatic beta cell function, in patients with type 2 diabetes
citation_author	Takahara, Mitsuyoshi
	Shiraiwa, Toshihiko
	Matsuoka, Taka-aki
	Yamamoto, Kaoru
	Maeno, Yoshifumi
	Shiraiwa, Yuka
	Yoshida, Yoko
	Katakami, Naoto
	Iijima, Hiroaki
	Katsumata, Hideyuki
	Arakawa, Kenji
	Hashimoto, Toshio
	Shimomura, Iichiro
citation_publisher	Dove Medical Press Ltd
citation_language	英語
citation_date	2020-11-18
citation_journal_title	Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
citation_volume	13
citation_firstpage	4457
citation_lastpage	4468
citation_doi	https://doi.org/10.2147/DMSO.S273396
citation_public_url	https://hdl.handle.net/11094/78261

Investigation of the effect of canagliflozin on the disposition index, a marker of pancreatic beta cell function, in patients with type 2 diabetes

閲覧可能ファイル

論文情報

論文詳細を表示